Neuble AI raises $350K seed from FuturePlay for brain disease diagnostic AI

Neuble AI raises $350K seed from FuturePlay for brain disease diagnostic AI

South Korean medical AI startup Neuble AI (뉴블에이아이) has raised 400 million won (~$350,000) in a seed round from domestic venture capital firm FuturePlay, according to a company announcement. The startup was co-founded by two professors at Gangnam Severance Hospital: Ahn Sung-jun from the Department of Radiology and Kim Ji-hoon from the Department of Radiation Oncology. Neuble AI's first commercial product, BrainCura (브레인큐라), is an AI-powered brain CT-based automated brain volume measurement solution. The company plans to launch BrainCura in the second half of 2027, targeting university hospitals, general screening centers, and regional dementia safety centers. A follow-up pipeline product, SynCura, which synthesizes high-resolution MRI-level images from CT scans for emergency stroke diagnosis, is expected to launch sequentially after BrainCura.

Why it matters: This is a small-scale seed round in medical AI, a segment where capital-efficient, clinically-anchored startups are emerging as alternatives to the capital-intensive foundation-model arms race. Neuble AI fits the pattern of clinician-founded vertical AI companies that address specific workflow bottlenecks — in this case, the long MRI wait times that delay brain disease diagnosis. The focus on leveraging CT imaging (which is cheaper, faster, and more widely available than MRI) for brain volume measurement and subsequent CT-to-MRI synthesis represents a practical, capital-efficient approach to expanding diagnostic access, particularly for neurodegenerative diseases like Alzheimer's where early screening is becoming more important with the advent of new drugs such as lecanemab.

Grounded expert take: Neuble AI's seed round is too small to register as a structural force in the AI capital cycle, but it exemplifies the continued formation of niche medical AI startups that are clinically grounded rather than purely technology-driven. The company's co-founder composition — both practicing clinicians — is a recurring pattern in healthcare AI that tends to produce more commercially viable products than generalist AI teams entering healthcare. The specific problem of converting CT scans into diagnostic-quality brain volume data addresses a real market gap as dementia screening volumes increase globally. However, the $350K round is pre-revenue and pre-regulatory, meaning the company faces significant execution risk in clinical validation, regulatory approval, and commercial adoption before the planned 2027 launch.

#NeubleAI #MedicalAI #BrainImaging #DementiaDiagnostics #HealthcareAI #SeedFunding